New combo therapy targets stomach cancer lymph nodes

NCT ID NCT07007182

Recruiting now Disease control Sponsor: Jinbo Yue Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether adding surgery and radiation to standard chemotherapy can improve outcomes for people with stomach cancer that has spread only to nearby lymph nodes. About 54 participants will receive either standard chemo or a more intensive plan including chemo, surgery, and radiation. The goal is to see if the combined approach helps control the disease longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SOX regimen (oxaliplatin plus S-1) or CAPEOX regimen (oxaliplatin plus capecitabine), with or without a PD-1 inhibitor
What this could lead to: If successful, this could offer a more effective treatment plan for gastric cancer patients with lymph node spread, potentially improving survival and disease control.
What could go wrong: This is a small, early-phase trial with only 54 participants, so results may not apply to all patients. The added treatments also carry risks like side effects from chemo and radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC ADENOCARCINOMA STOMACH NEOPLASMS

Contacts and locations

Locations

Shandong Cancer Hospital and Institute
RECRUITING

Jinan, Shandong, 250117, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.